$LJPC News

Last published 4y ago

4y agoINVA LJPCInnoviva Completes Acquisition of La Jolla PharmaceuticalBusiness WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares o
4y agoINVA LJPC RPRXInnoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressBusiness WireRoyalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $
4y agoINVA LJPCInnoviva to Acquire La Jolla Pharmaceutical CompanyBusiness WireAcquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovativ
4y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate ProgressBusiness WireLa Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended M
4y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate ProgressBusiness WireLa Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve mon
4y agoLJPCPilot RCT of Angiotensin II vs. Vasopressin in Septic Shock - NCT05193370ClinicalTrials.govEfficacy in increasing blood pressure (BP) at 3 hours post-drug initiation, BP goal at other time points, Time to shock reversal, (and 12 more...)
4y agoLJPCLa Jolla Pharmaceutical Company Announces Share Repurchase PlanBusiness WireLa Jolla Pharmaceutical Company (NASDAQ:LJPC) today announced that it will commence a share repurchase plan for up to $10 million of the Company's common stock. Repurchases may be made from time to time at the Company's discretion. The plan has no time
5y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate ProgressBusiness WireLa Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine month
5y agoLJPCTony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical CompanyBusiness WireLa Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FC
5y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate ProgressBusiness WireLa Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months
5y agoABEO GEO LJPC NAKD+1Thinking about buying stock in La Jolla Pharmaceutical, The GEO Group, Abeona Therapeutics, Sellas Life Sciences, or Naked Brand?PR NewswireNEW YORK, June 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LJPC, GEO, ABEO, SLS, and NAKD. To
5y agoLJPCAngiotensin II for Distributive Shock - NCT04904562ClinicalTrials.govTotal catecholamine dose, Cumulative time spent with MAP < 70 mmHg, Time to extubation, (and 8 more...)
5y agoLJPCAngiotensin II in Liver Transplantation - NCT04901169ClinicalTrials.govTotal dose of norepinephrine (NE), averaged over case duration and total body weight, utilized during liver transplantation (LT) to maintain mean arterial pressure (MAP) greater than or equal to 65 mmHg., Proportion of patients requiring 3rd and 4th line vasopressor infusions (epinephrine or vasopressin) during LT, Time spent below target MAP (65 mmHg), (and 13 more...)
5y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate ProgressBusiness WireLa Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the thre
5y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Corporate ProgressBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress.
5y agoLJPCLa Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in EuropeBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and i ...
6y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020Business WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2020.
6y agoLJPCAngiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients - NCT04529005ClinicalTrials.govBlood Pressure - Intraoperative, Blood Pressure - Postoperative, Arrhythmias, (and 9 more...)
6y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate ProgressGlobeNewswireSAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that...
6y agoLJPCLarry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical CompanyGlobeNewswireSAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive...
6y agoLJPCLa Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.GlobeNewswireSAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of...
6y agoLJPC TTPHLa Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.GlobeNewswireLa Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative...
6y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2020GlobeNewswireSAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes...
6y agoLJPCLa Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, BelgiumGlobeNewswireSAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
6y agoLJPCLa Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in GermanyGlobeNewswireSAN DIEGO, April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
6y agoLJPCLa Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in GermanyGlobeNewswireSAN DIEGO, April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
6y agoLJPCLa Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) in Italy for Compassionate Use in Patients with Septic Shock Associated with COVID-19GlobeNewswireSAN DIEGO, March 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
6y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2019GlobeNewswireSAN DIEGO, March 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
6y agoMBRX LJPC INSM TEVA+1R&D Leading to Supported Progress for Treating Acute Myeloid Leukemia (AML)PR NewswireAcute Myeloid Leukemia (AML) research has seen great progress with more researchers are now studying the causes, diagnosis, and treatment of Acute...
6y agoLJPCLa Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019GlobeNewswireSAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
6y agoLJPCLa Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical ResultsGlobeNewswireSAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
6y agoLJPCLa Jolla Pharmaceutical Company Announces Management TransitionGlobeNewswireSAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
7y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate ProgressGlobeNewswireSAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
7y agoLJPCLa Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)GlobeNewswireSAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to...
8y agoLJPCLa Jolla Pharmaceutical Co (LJPC) CEO George Tidmarsh on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate ProgressBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and nine months ended September 30, 2017 and highlighted recent corporate progress.
9y agoLJPCLa Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018Business WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued favorable Scientific Advice regarding the EU regulatory pathway for LJPC-501 (angiotensin II) for the treatment of hypotension in adults with distributive or vasodilatory shock ...
9y agoLJPCPrespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II StateBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced an abstract entitled "Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II" has been selected for presentation at the upcoming 30th European Society of Intensive Care Medicine (ESICM) LIVES Annual Congress being held September 2 ...
9y agoLJPCLa Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501Business WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for the investigational drug LJPC-501 (angiotensin II) for the treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite ...
9y agoLJPCLa Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501Business WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), today announced that the Company has initiated an expanded access program (EAP) in the United States to provide its investigational drug, LJPC-501 (angiotensin II), to patients with vasodilatory or distributive shock who cannot achieve target mean arterial pressure (MAP) despite adequate fluid res ...
9y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate ProgressBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and six months ended June 30, 2017 and recent corporate progress.
9y agoLJPCResults of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of MedicineBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) have been published online by The New England Journal of Medicine (NEJM). The article, entitled “Angiotensin II for the Treatment of Vasodilatory Shock,” also will be publ ...
9y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate ProgressBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three months ended March 31, 2017 and recent corporate progress.
9y agoLJPCLa Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common StockBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten public offering of approximately 3.7 million shares of common stock, offered at a price of $33.50 ...
9y agoLJPCLa Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common StockBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced its intention to offer and sell $100,000,000 of its common stock in an underwritten public offering pursuant to its existing shelf ...
9y agoLJPCLa Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501Business WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla), today announced positive top-line results from the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) in patients with catecholamine resistant hypotension (CRH).
9y agoLJPCLa Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate ProgressBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2016 financial results and highlighted 2016 corporate progress.
10y agoLJPCLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate ProgressBusiness WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and nine months ended September 30, 2016 and recent corporate progress.
10y agoLJPCLa Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401Business WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending LJPC-4 ...
10y agoLJPCLa Jolla Pharmaceutical Company Announces Agreement with European Medicines Agency on Pivotal Study of LJPC-401Business WireSAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has reached agreement with the European Medicines Agency (EMA) on the design of a pivotal study of LJPC-401, La Jolla’s novel ...